Risk of bias: a simulation study of power to detect study-level moderator effects in meta-analysis.

被引:109
作者
Hempel S. [1 ]
Miles J.N. [1 ]
Booth M.J. [1 ]
Wang Z. [1 ]
Morton S.C. [1 ]
Shekelle P.G. [1 ]
机构
[1] RAND Corporation, Santa Monica, 90407, CA
基金
美国医疗保健研究与质量局;
关键词
Meta-analysis; Power; Heterogeneity; Meta-epidemiological dataset; Randomized controlled trial (RCT);
D O I
10.1186/2046-4053-2-107
中图分类号
学科分类号
摘要
There are both theoretical and empirical reasons to believe that design and execution factors are associated with bias in controlled trials. Statistically significant moderator effects, such as the effect of trial quality on treatment effect sizes, are rarely detected in individual meta-analyses, and evidence from meta-epidemiological datasets is inconsistent. The reasons for the disconnect between theory and empirical observation are unclear. The study objective was to explore the power to detect study level moderator effects in meta-analyses. We generated meta-analyses using Monte-Carlo simulations and investigated the effect of number of trials, trial sample size, moderator effect size, heterogeneity, and moderator distribution on power to detect moderator effects. The simulations provide a reference guide for investigators to estimate power when planning meta-regressions. The power to detect moderator effects in meta-analyses, for example, effects of study quality on effect sizes, is largely determined by the degree of residual heterogeneity present in the dataset (noise not explained by the moderator). Larger trial sample sizes increase power only when residual heterogeneity is low. A large number of trials or low residual heterogeneity are necessary to detect effects. When the proportion of the moderator is not equal (for example, 25% 'high quality', 75% 'low quality' trials), power of 80% was rarely achieved in investigated scenarios. Application to an empirical meta-epidemiological dataset with substantial heterogeneity (I(2) = 92%, τ(2) = 0.285) estimated >200 trials are needed for a power of 80% to show a statistically significant result, even for a substantial moderator effect (0.2), and the number of trials with the less common feature (for example, few 'high quality' studies) affects power extensively. Although study characteristics, such as trial quality, may explain some proportion of heterogeneity across study results in meta-analyses, residual heterogeneity is a crucial factor in determining when associations between moderator variables and effect sizes can be statistically detected. Detecting moderator effects requires more powerful analyses than are employed in most published investigations; hence negative findings should not be considered evidence of a lack of effect, and investigations are not hypothesis-proving unless power calculations show sufficient ability to detect effects.
引用
收藏
相关论文
共 106 条
[1]  
Verhagen AP(2001)The art of quality assessment of RCTs included in systematic reviews J Clin Epidemiol 54 651-654
[2]  
de Vet HC(2005)Assessment of methodological quality of primary studies by systematic reviews: results of the metaquality cross sectional study BMJ 330 1053-1524
[3]  
de Bie RA(2002)Statistical methods for assessing the influence of study characteristics on treatment effects in ‘meta-epidemiological’ research Stat Med 21 1513-239
[4]  
Boers M(2007)Required sample size to detect the mediated effect Psychol Sci 18 233-454
[5]  
van den Brandt PA(1989)How study design affects outcomes in comparisons of therapy. I: Medical Stat Med 8 441-412
[6]  
Moja LP(1995)Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials JAMA 273 408-613
[7]  
Telaro E(1998)Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352 609-1692
[8]  
D’Amico R(2009)Empirical evidence of an association between internal validity and effect size in randomized controlled trials of low-back pain Spine (Phila Pa 1976) 34 1685-352
[9]  
Moschetti I(1990)An empirical study of the possible relation of treatment differences to quality scores in controlled randomized clinical trials Control Clin Trials 11 339-2982
[10]  
Coe L(2002)Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials JAMA 287 2973-46